Physician profile

Brian Conway

Cardiovascular Disease · Dallas, TX

NPI 1699209106

$17,047.28

in general payments reported to CMS, 2019-2025

37 companies · $3,598 in 2025

The $3,598 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Grant$8,000.00
Food and Beverage$4,412.83
Travel and Lodging$2,932.47
Education$165.28

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic, INC. $8,349.08 2021-2025 Onyx Frontier
Abbott Laboratories $2,222.52 2021-2025 Amplatzer Amulet, Triclip, Diamondback Coronary
Edwards Lifesciences Corporation $1,871.15 2022-2024 Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia
Abiomed $891.97 2022-2025 Impella
Boston Scientific Corporation $603.29 2021-2025 Farapulse
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $385.25 2021-2025 Lifevest
Boehringer Ingelheim Pharmaceuticals, INC. $347.34 2021-2025 Jardiance
Irhythm Technologies, INC. $312.57 2022
Shockwave Medical, INC $303.71 2023-2025 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Kestra Medical Technology Services, INC. $269.42 2025 Assure Wcd
Merck Sharp & Dohme LLC $175.85 2024-2025 Verquvo, Winrevair
Bayer Healthcare Pharmaceuticals INC. $152.29 2024-2025
Cordis US Corp. $102.06 2023 Mynx Control
Actelion Pharmaceuticals US, INC. $99.91 2025 Uptravi
Heartflow, INC. $88.44 2025
Show all 37 companies
CompanyGeneral paymentsYearsTop products
Cathworks, INC. $84.12 2023 Ffrangio
Lantheus Medical Imaging, INC. $75.60 2021
Terumo Medical Corporation $74.75 2023 Glidesheath Slender, Glidewire, Navicross
Penumbra, INC. $63.06 2023 Indigo System
Inspire Medical Systems, INC. $54.84 2025 Inspire
Bridgebio Pharma, INC. $52.78 2025 Attruby
Gilead Sciences, INC. $44.62 2024
Novartis Pharmaceuticals Corporation $43.37 2025
Biosense Webster, INC. $38.68 2025 Nuvision Ice Catheter
Pfizer INC. $37.96 2021-2025
Teleflex LLC $33.72 2023 Guideliner
Amgen INC. $30.96 2024-2025 Repatha, Repatha
Novo Nordisk INC $30.22 2025 Wegovy
Sensible Medical Innovations INC $27.65 2025 Reds System
Baxter Healthcare $26.86 2025 Hillrom - Cardiac Ambulatory Monitor
Kiniksa Pharmaceuticals International, Plc $25.97 2024 Arcalyst
E.R. Squibb & Sons, L.L.C. $24.90 2025 Eliquis
Janssen Pharmaceuticals, INC $22.98 2023 Xarelto
Philips North America LLC $22.88 2022
Glaxosmithkline, LLC. $22.08 2025 Arexvy
Acist Medical Systems, INC. $18.46 2024
Vital Connect, INC $15.97 2025 Vitalpatch Rtm

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Brian Conway

$17,047.28

in general payments reported 2019-2025

Years
2021-2025
Top company
Medtronic, INC.
Context
The $3,598 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/9175824/brian-conway

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.